267 related articles for article (PubMed ID: 36591249)
1. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study.
Wang D; Shan C; Liu J; Zhang R; Zhu G; Gao T; Chang H; Gao S; Bai C; Nie N; Zhang Q; Lin Y
Front Immunol; 2022; 13():1067721. PubMed ID: 36591249
[TBL] [Abstract][Full Text] [Related]
2. Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study.
Roberts JE; Burn C; Sadun RE; Smitherman EA; Wenderfer SE; Son MBF
Lupus; 2023 Aug; 32(9):1111-1116. PubMed ID: 37410059
[TBL] [Abstract][Full Text] [Related]
3. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
4. Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study.
Yamane T; Hashiramoto A
Lupus; 2024 May; 33(6):598-607. PubMed ID: 38509864
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study.
Wang L; Liang X; Cao Z; Wang D; Luo Y; Feng Y; Luo C; Zhi S; Huang Y; Fan Z; Wang C; Liu H; Liu J; Zhang T; Cheng Q; Xie X; Shuai L; Rong Z; Zeng P; Yu H; Lu M; Sun L; Yang S; Zhao D; Zhang W; Wu X; Li Q; Wang Y; Zhang Q; Yang J; Li X; Song H; Tang X
Rheumatology (Oxford); 2024 May; 63(5):1437-1446. PubMed ID: 37606970
[TBL] [Abstract][Full Text] [Related]
6. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of belimumab treatment in childhood-onset systemic lupus erythematosus].
Kang M; Zhu J; Xu YJ; Li SN; Lai JM
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3881-3885. PubMed ID: 36540927
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
9. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting.
Anjo C; Mascaró JM; Espinosa G; Cervera R
Scand J Rheumatol; 2019 Nov; 48(6):469-473. PubMed ID: 31264525
[No Abstract] [Full Text] [Related]
11. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study.
Nakai T; Fukui S; Sawada H; Ikada Y; Tamaki H; Kishimoto M; Okada M
Lupus; 2023 Nov; 32(13):1518-1527. PubMed ID: 37858981
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
Fan Q; Yang H; Liu Y
Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
[TBL] [Abstract][Full Text] [Related]
14. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
16. Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
Nakai T; Fukui S; Kidoguchi G; Ikeda Y; Kitada A; Nomura A; Tamaki H; Kishimoto M; Okada M
Clin Rheumatol; 2022 Dec; 41(12):3735-3745. PubMed ID: 35939162
[TBL] [Abstract][Full Text] [Related]
17. Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids.
Lee YJ; Ahn SM; Hong S; Oh JS; Lee CK; Yoo B; Kim YG
Korean J Intern Med; 2024 Mar; 39(2):338-346. PubMed ID: 38031366
[TBL] [Abstract][Full Text] [Related]
18. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
19. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
[TBL] [Abstract][Full Text] [Related]
20. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]